# A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease

> **NCT07120152** · — · NOT_YET_RECRUITING · sponsor: **Erwin Dreesen** · enrollment: 439 (estimated)

## Conditions studied

- IBD - Inflammatory Bowel Disease
- RA - Rheumatoid Arthritis

## Interventions

- **DRUG:** Subcutaneous infliximab CT-P13 Remsima®SC

## Key facts

- **NCT ID:** NCT07120152
- **Lead sponsor:** Erwin Dreesen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 439 (ESTIMATED)
- **Last updated:** 2025-09-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07120152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07120152, "A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07120152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*